US FDA requires new warnings for gadolinium-based contrast agents
This article was originally published in SRA
Executive Summary
US manufacturers of gadolinium-based contrast agents will have to change their product labels to include warnings about the risk of nephrogenic systemic fibrosis associated with the use of the drugs in patients with kidney disease, the Food and Drug Administration has said1,2.